Objective: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.
C affeine has a dose-dependent inverse association with the risk of developing Parkinson disease (PD). 1, 2 Caffeine is an antagonist at adenosine A2a receptors, although a recent study suggested that it may act as an A2a inverse agonist. 3 Both caffeine and other more specific A2a receptor antagonists are neuroprotective in toxin-induced PD animal models. 4 Furthermore, mice lacking the A2a receptor are protected against dopaminergic neurodegeneration induced by mutant α-synuclein. 5 These data have led to the hypothesis that caffeine may have a neuroprotective effect in PD. As a preliminary test of this hypothesis, we previously analyzed data from 2 phase 2 futility-design clinical studies of potential disease-modifying therapies in PD. Arms in the studies included creatine, minocycline, and placebo in 1 study (Futility Study 1 [FS1]) 6 and coenzyme Q10, GPI-1485 (an immunophilin ligand), and placebo in the other (FS2). 7 A caffeine intake questionnaire was completed by participating subjects. Unexpectedly, among subjects randomized to creatine, increasing levels of caffeine intake were associated with significantly faster progression of PD as measured by the change in the total Unified Parkinson Disease Rating Scale (UPDRS) score, whereas there was no consistent association of caffeine with progression in other treatment groups. 8 We sought to replicate and extend this surprising but potentially important observation by analyzing the association of caffeine intake with the rate of progression of PD as a substudy of a large multicenter double-blind, placebo-controlled phase 3 clinical study of creatine as a potentially disease-modifying therapy in PD, the "Large Long Term Study" (LS1). 9 
METHODS

Study Subjects and the LS1 Study
A total of 1741 subjects with early PD (diagnosed within 5 years) already treated with dopaminergic therapy were enrolled in LS1 and randomized 1:1 to creatine 10 g/d or placebo. Subjects were recruited from 45 sites in the United States and Canada. All subjects were within 5 years from diagnosis and were receiving dopaminergic therapy (levodopa or a dopamine agonist) for at least 90 days but no more than 2 years at the time of recruitment into the study. This study was sponsored by the National Institute of Neurological Disorders and Stroke. Details of the study design and characteristics of participants have been published elsewhere. 9, 10 The goal was to follow all subjects for a minimum of 5 years; however, a preplanned interim analysis conducted when half of the subjects had reached the 5-year time point suggested that creatine was unlikely to meet the prespecified threshold for significant slowing of clinical disease progression, and the study was terminated early. All study procedures were approved by institutional review boards at each participating site.
Caffeine Questionnaire
A total of 1549 subjects completed a caffeine intake questionnaire that had been used previously in the FS1. 8 This questionnaire focused primarily on intake of caffeinated beverages during the previous week. The majority of subjects who completed the questionnaire did so at the 18-month time point of the study. In this analysis, we did not take into account those who did not complete a questionnaire, but data comparing characteristics of those who completed or did not complete the caffeine questionnaire are presented.
Statistical Methods
The primary outcome measure was the total UPDRS score during all years of follow-up, with baseline UPDRS included as a covariate. For all analyses (baseline and follow-up), we defined "total UPDRS" as the sum of scores for a participant for UPDRS parts I to III. The UPDRS was selected a priori for this analysis as this measure was used in our previous study based on data from the FS1 and FS2. 8 We sought to determine whether we could replicate the results of that previous study in the current analysis of data from the larger and longer duration LS1. The distribution of daily caffeine consumption was zero-inflated and highly skewed to the right. A log and square root transformation did not lead to normally distributed data because of the high percentage of zero values. Therefore, caffeine was analyzed as a categorical variable, with subjects split into high-and low-caffeine intake groups. The low-caffeine group was defined as subjects with daily caffeine intake less than or equal to 300 mg. The highcaffeine group had caffeine intakes greater than 300 mg/d. This cutoff of 300 mg has been used in previous studies (Ascherio, 2001 #645; Fernandez-Duenas, 2014 #3085; Ross, 2000 #644; and Schwarzschild, 2003 #3082) of health-related impacts of caffeine consumption.
Baseline characteristics were compared for the low-(n = 1288) and high-(n = 261) caffeine groups. P values from Wilcoxon and χ 2 tests were obtained for continuous and binary variables, respectively.
To assess the effect of caffeine while adjusting for other covariates and interactions, a mixed model was used with site as random effect. The response variable was the annual total UPDRS score from years 1 to 5. The mixed model used all available longitudinal annual measurements of UPDRS, assuming the correlation structure of multiple measurements within each individual to be heterogeneous first-order autoregressive. The autoregressive (order 1) structure assumes that the correlation of yearly UPDRS is mainly related to measurements in neighboring years and the relationships decrease as the time between measurements increases. The heterogeneous structure relaxed the variance assumption for each measurement and allows a different variance at each time point.
Models were fit by SAS PROC MIXED using Restricted Maximum Likelihood method. Fixed effect parameters were estimated for every model. REML in PROC MIXED accommodates data that are missing at random. Missing data in our sample were mostly due to loss of follow-up, dropouts, or deaths. Loss of follow-up here refers to loss due to early trial closure; dropouts seemed to be unrelated to caffeine and thus were considered missing at random as well. Death could be considered missing at random only if the reason for death was not related to caffeine consumption. There was no association of caffeine intake with cardiac death in this data set, a cause of death that, in theory, might have been related to caffeine, so death also was considered missing at random.
We fit the basic model using caffeine category (high vs low) along with other variables of clinical interest, which included treatment group, age at enrollment, years since enrollment, baseline UPDRS score, and sex as main effects. Treatment-by-caffeine interaction, treatment-by-sex interaction, and year interactions with treatment, caffeine, age, sex, and baseline UPDRS, as well as the 3-way interactions of treatment by caffeine by year, treatment by sex by year, and caffeine by sex by year, were tested for their significance by interaction plots and Wald test P values. The final basic model included significant main effects at the 0.05 level and significant interactions at the 0.1 level. Next, we assessed the confounding and modifying effect of covariates that might associate with caffeine or disease progression. First, the pairwise correlation was computed between continuous variables. To avoid multicollinearity, variables that were highly correlated were not both kept in the model. Each covariate was added to the basic model to test its influence on disease progression. Their interaction with caffeine also was tested by 2-and 3-way interactions with time. Wald test with P values less than 0.05 for main effects and 0.1 for interaction terms were used to select variables for the final model. Main effects remained in the model if any interactions including this main effect were significant. Final model diagnostics checked the normality of the residual plot and the pattern of residual versus predictors. If a significant interaction of treatment (creatine vs placebo) by caffeine group was detected, separate models for treatment groups were built to assess the effect of caffeine in the different groups.
RESULTS
Baseline characteristics of the 1549 subjects who completed the caffeine questionnaire and for the 192 subjects who did not are shown in Table 1 . Most baseline characteristics were not significantly different between these 2 groups. Subjects who did not provide caffeine intake data had significantly higher baseline Beck Depression Inventory (BDI) scores, UDPRS scores, and levodopa dose equivalents, suggesting that depressive symptoms or more severe PD symptoms may have reduced the chances of completing the caffeine questionnaire.
The distribution of caffeine intake is shown in Figure 1 . Table 2 compares baseline characteristics for subjects in the high-and low-caffeine groups. Uric acid levels were compared because of the association of uric acid levels with rate of progression of PD 11 and reports that high caffeine intake may be associated with lower uric acid levels. 12 Median uric acid levels and median body mass index (BMI) were significantly higher in subjects in the high-caffeine group, whereas days since diagnosis at the time of study entry were lower in the high-caffeine group. A significantly lower percentage of female subjects was present in the highversus low-caffeine group.
In the final model, there was a significant 3-way interaction between treatment group (creatine vs placebo), caffeine category (high vs low), and years since enrollment in assessing the association with total UPDRS score (ie, rate of progression). Therefore, the placebo and creatine groups were analyzed separately. For the placebo group, caffeine and rate of progression did not interact. In contrast, there was a significant interaction between caffeine and rate of progression for the creatine group, with high caffeine intake being associated with more rapid progression ( Fig. 2 and Table 3 ; P = 0.002). Uric acid was not statistically significant in either model (Ps > 0.1) and so was not included in the model based on our model selection criteria.
The lack of an interaction between caffeine and rate of progression in the placebo group is consistent with a similar analysis in a previously published study. 8 However, it remains possible that even modest levels of caffeine below the 300-mg cutoff used for our primary analysis might be associated with slowing of clinical progression of PD, which would limit our ability to detect an association of caffeine with rate of progression using the 300-mg threshold. To address this possibility, we conducted an additional post hoc analysis of caffeine and rate of progression comparing subjects with very low caffeine intake (<25 mg/d, n = 662) with those in the high-caffeine group (>300 mg/d, n = 261), and again, there was a lack of a significant interaction in the placebo group.
An interesting possibility raised by these results is that the association of high caffeine intake with a faster rate of progression among subjects taking creatine may have masked a protective effect of creatine among subjects with low levels of caffeine intake. However, subgroup analyses restricted to subjects in the low-caffeine group (<300 mg/d, n = 1288) or the very low-caffeine group (<25 mg/d, n = 662) revealed no significant associations of treatment (creatine vs placebo) and rate of progression of PD.
DISCUSSION
Epidemiological data indicate a dose-dependent association of caffeine intake with the risk of PD. 1,2 Furthermore, caffeine is neuroprotective in animal models of PD, 4 raising the possibility that caffeine also may have neuroprotective effects in patients with FIGURE 1. Distribution of daily caffeine intake. Distribution of daily caffeine intake among the 1549 subjects for whom caffeine intake data were available. The mean intake was 134.8 mg/d. PD. Therefore, we predicted that high caffeine intake would be associated with slower progression of PD. Contrary to this prediction, we found that, among patients randomized to take creatine, higher caffeine intake was associated with a significantly faster rate of progression of PD, whereas there was no significant association detected for caffeine with the rate of progression among placebo subjects.
In a previous study of 2 smaller clinical cohorts, we similarly found no association of caffeine intake with the rate of progression of PD 8 for 12 months. This previous study also unexpectedly identified a significant association of caffeine with a faster rate of progression among subjects taking creatine, but this finding was not considered to be definitive due to the small number of subjects in that study (n = 64 subjects on creatine), the lack of an a priori prediction of this result, and a result of borderline significance. In contrast, the current study included clinical progression data for up to 5 years from 1549 subjects. Furthermore, based on the results of the previous study, for the current study, we specifically hypothesized a priori that higher caffeine intake would be associated with faster progression among subjects taking creatine. Indeed, we confirmed this result (P = 0.002), suggesting a deleterious interaction between caffeine and creatine with respect to the rate of clinical progression of PD. Although data on the frequency of combined use of creatine and caffeine in the general population are not available, caffeine use is common, with 17% of subjects with PD in the LS1 study having intakes greater than 300 mg/d. Creatine supplements also are common among certain populations, with 1 study suggesting that 50% of high school senior football players are using creatine supplements. 13 However, the prevalence of creatine use in the general population with PD is unknown. The current study was restricted to patients with PD, and so it remains unknown whether there may be a deleterious interaction between creatine and caffeine use in people who do not have PD or in a younger population.
The LS1 trial of creatine ended early for futility based on a preplanned interim analysis. Our observation of a faster rate of progression among subjects with high levels of caffeine intake raises the interesting possibility that creatine may actually have had a beneficial effect among subjects with lower levels of caffeine intake, but this effect was negated by the deleterious effect among subjects with high levels of caffeine intake. However, no significant association of creatine with rate of progression of PD even was detected when considering only those subjects in the low-caffeine group (<300 mg/d) or only those subjects with very low caffeine intake (<25 mg/d).
Recent data have suggested that caffeine may have a symptomatic benefit in PD. 14 We observed a similar mean levodopa equivalent dose at baseline among subjects in the low-and highcaffeine groups and a nonsignificant trend toward lower baseline UPDRS scores in the high-caffeine group. However, because this study was not randomized with respect to caffeine intake, the lower baseline UPDRS scores do not necessarily imply a symptomatic benefit from caffeine. In any case, a symptomatic effect of caffeine on PD symptoms should not complicate our analysis of the association of caffeine intake with progression of PD unless either the level of caffeine intake changes during the study or the magnitude of the symptomatic benefit of caffeine changes as the disease progresses.
The potential mechanism by which caffeine and creatine may negatively interact with respect to the rate of progression of PD is not addressed in the current study. A previous study suggested that caffeine completely negates the effects of creatine on muscle contraction, 15, 16 potentially by counteracting the creatine associated facilitation of calcium uptake by the sarcoplasmic reticulum. 16 It is interesting to note that high caffeine intake was associated with a mild but significant increase in uric acid levels ( Table 2 ). This contrasts with previous reports of an association of caffeine with lower serum uric acid levels 17 and suggests that the relationship between caffeine intake and uric acid level may be different in patients with PD compared with the general population. Uric acid is an antioxidant, and high uric acid levels have been associated with a lower risk of PD and with a slower rate of progression of PD. 18 However, despite the higher uric acid levels in the high-caffeine group, we did not detect an association of high caffeine use with a slower rate of progression of PD.
This study has several strengths, including a large population of patients with PD with detailed clinical assessments by movement disorders specialists for several years, as well as availability of data on caffeine intake for a majority of the subjects. There also are limitations. Caffeine data were collected at only 1 time point during the study, and this was 18 months after baseline. Therefore, our analyses could not account for potential changes in levels of caffeine intake during the course of the study. In our previously published study, a repeat caffeine questionnaire was administered after 1 year, and this demonstrated that the level of caffeine intake was relatively stable (changed by less than 25%) in approximately 90% of the subjects. 8 However, the percentage of subjects with changes in caffeine intake likely is greater in the current study due to its longer duration. Not all participants provided caffeine data, although baseline differences between those who provided data and those who did not were minimal. The most important drawback is that subjects were not randomized or blinded with respect to caffeine intake. It is possible that other factors that are associated with caffeine use could influence these results. Relating to this point, data on smoking were not collected for the LS1 subjects. There is an association with caffeine and tobacco use. 19 This raises the possibility that the associations with caffeine reported in this study may reflect an influence of tobacco use. However, the current results replicate our previous report that caffeine use is inversely associated with rate of clinical progression of PD in subjects taking creatine, and results in the previous study remained significant after adjusting for smoking. 8 Similarly, in a study by Hamza et al 4 identifying GRIN2A genotype as a modifier of the influence of caffeine on the risk of PD, the results were similar before and after adjusting for smoking. Furthermore, the frequency of smoking is low in patients with PD, 19 and so, this issue is likely to be relevant to only a small percentage of LS1 subjects. A case control study of more than 500 patients with PD and a similar number of controls at movement disorders centers in the United States revealed that only 3.6% of subjects with PD smoked cigarettes and also had significant caffeine intake 20 (Tanner et al, unpublished data ).
An additional possible limitation is the retrospective selfreported nature of the caffeine questionnaire, although studies on caffeine intake quantification have documented the validity of self-report methods. 21 In conclusion, these data show no association of caffeine with the rate of clinical progression of PD except in the group of participants taking creatine where progression was increased. This study was not randomized or blinded with respect to caffeine intake. For this reason, and based on the strength of epidemiological and preclinical data suggesting that caffeine may have neuroprotective effects in PD, further study of the potential neuroprotective effects of caffeine and other A2a receptor antagonists remains warranted. Given the lack of any benefits of creatine for patients with PD in the LS1 study, as well as the possibility of a deleterious effect when combined with caffeine, it remains prudent to recommend against creatine supplementation for patients with PD. 
